Publication: Antimalarial drug resistance and combination chemotherapy
Issued Date
1999-04-29
Resource Type
ISSN
09628436
Other identifier(s)
2-s2.0-0033614329
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Philosophical Transactions of the Royal Society B: Biological Sciences. Vol.354, No.1384 (1999), 739-749
Suggested Citation
Nicholas White Antimalarial drug resistance and combination chemotherapy. Philosophical Transactions of the Royal Society B: Biological Sciences. Vol.354, No.1384 (1999), 739-749. doi:10.1098/rstb.1999.0426 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/25283
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Antimalarial drug resistance and combination chemotherapy
Author(s)
Other Contributor(s)
Abstract
Antimarial drug resistance develops when spontaneously occurring parasite mutants with reduced susceptibility are selected, and are then transmitted. Drugs for which a single point mutation confers a marked reduction in susceptibility are particularly vulnerable. Low clearance and a shallow concentration-effect relationship increase the chance of selection. Use of combinations of antimalarials that do not share the same resistance mechanisms will reduce the chance of selection because the chance of a resistant mutant surviving is the product of the per parasite mutation rates for the individual drugs, multiplied by the number of parasites in an infection that are exposed to the drugs. Artemisinin derivatives are particularly effective combination partners because (i) they are very active antimalarials, producing up to 10 000-fold reductions in parasite biomass per asexual cycle; (ii) they reduce malaria transmissibility; and (iii) no resistance to these drugs has been reported yet. There are good arguments for no longer using antimalarial drugs alone in treatment, and instead always using a combination with artemisinin or one of its derivatives.